Get the Stockscreener App
472.95
1.33%
6.19
After Hours:
473.06
0.11
+0.02%
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $472.95, with a volume of 1.86M.
It is up +1.33% in the last 24 hours and down -3.12% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$466.76
Open:
$471.155
24h Volume:
1.86M
Relative Volume:
0.86
Market Cap:
$175.76B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
26.00
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
+1.43%
1M Performance:
-3.12%
6M Performance:
-16.44%
1Y Performance:
+16.20%
1-Day Range:
$466.60
$477.42
1-Week Range:
$459.64
$481.83
52-Week Range:
$385.46
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
472.95 | 173.46B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.92 | 123.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
579.23 | 44.71B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
349.53 | 33.65B | 3.77B | 449.25M | 516.49M | 8.7322 |
A
Agilent Technologies Inc
|
117.69 | 33.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider - PharmiWeb.com
Thermo Fisher Scientific’s Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials - The Joplin Globe
Thermo Fisher Scientific Introduces Gibco CTS DynaXS Single Use Bioreactor - Contract Pharma
International Markets and Thermo Fisher (TMO): A Deep Dive for Investors - Yahoo Finance
Thermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing - BioPharma APAC
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing - The Joplin Globe
What Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Doing? - Yahoo Finance
Thermo Fisher Scientific Increases Quarterly Dividend - The National Law Review
Thermo Fisher's $1.08B Microbiology Sell-Off: A Procurement and Operations Briefing for Lab Managers - Lab Manager
Sandro Wealth Management LLC Makes New $2.09 Million Investment in Thermo Fisher Scientific Inc. $TMO - MarketBeat
PFA Pension Forsikringsaktieselskab Purchases New Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat
Thermo Fisher Scientific Q1 2026 Financial Results and SEC 10-Q Filing Summary - Minichart
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market - MarketWatch
Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Billionaire Investor Takes New Stake In Thermo Fisher Scientific - Yahoo Finance
Thermo Fisher (NYSE: TMO) grows Q1 revenue and closes $9.1B Clario deal - Stock Titan
Thermo Fisher Scientific Inc. $TMO Shares Sold by Danica Pension Livsforsikringsaktieselskab - MarketBeat
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610 - marketscreener.com
Vanguard (NYSE: TMO) reports 28.0M shares of Thermo Fisher, 7.53% stake - Stock Titan
Thermo Fisher Scientific opens bioprocess design center in Massachusetts - chemengonline.com
Soil Testing Equipment Market Size, Share & Growth Outlook - openPR.com
Thermo Fisher Scientific Agrees to Divest Its Microbiology Business to Astorg - ChemAnalyst
PowerFlex thermal cycler boosts PCR flexibility & speed - SelectScience
Molecular Quality Controls Market | THERMO FISHER SCIENTIFIC, INC, Qnostics, Zeptometrix Corporation etc. - openPR.com
Thermo Fisher Scientific Expands Plainville Facility With Flagship Bioprocess Design Center To Advance Biologics Development - BioPharma APAC
Insider Sell: Gianluca Pettiti Sells Shares of Thermo Fisher Sci - GuruFocus
Thermo Fisher Scientific Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Thermo Fisher Scientific president & COO sells $185,064 in stock - Investing.com
Thermo Fisher Scientific president & COO sells $185,064 in stock By Investing.com - Investing.com UK
Thermo Fisher Scientific (NYSE:TMO) COO Sells $185,064.00 in Stock - MarketBeat
Thermo Fisher (NYSE: TMO) COO executes 400-share Rule 10b5-1 sale - Stock Titan
Thermo Fisher Scientific to sell its microbiology business as Astorg - chemengonline.com
Thermo Fisher Scientific launches applied Biosystems PowerFlex Thermal Cycler - Med-Tech Insights
Thermo Fisher Scientific, SHL Medical Collaborate on Integrated Drug-Device Solutions - Medical Product Outsourcing
Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)? - Insider Monkey
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies - BioSpace
Thermo Fisher Scientific to Host Investor DayApril 28, 2026 - BioSpace
Thermo Fisher to Sell Microbiology Business to Astorg - WSJ
Thermo Fisher opens Plainville design center amid $2B push for U.S. manufacturing - The Business Journals
Thermo Fisher sells microbiology business for $1B - BioWorld News
Thermo Fisher agrees to sell microbiology business to Astorg in $1bn deal - Medical Device Network
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of - PharmiWeb.com
Thermo Fisher inks $1.1B deal to sell microbiology unit to Astorg - MedTech Dive
Thermo Fisher Scientific Opens Flagship U.S. Bioprocess Design Center in MA - Contract Pharma
Thermo Fisher Stock Fell After Q1 2026 Earnings. Is TMO a Buy? - TIKR.com
New York event: Thermo Fisher executives take questions May 20 - Stock Titan
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg - Lelezard
Medical Refrigerators Market Competitive Analysis to 2028 | - openPR.com
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):